CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 114 enrolled
Drug / intervention
decitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01687400
NCT01687400Phase 2Completed
CompareCT.gov

Genomic Predictors of Decitabine Response in AML/MDS

Washington University School of Medicine·interventional·Posted Sep 18, 2012·Updated Oct 2, 2018

In Brief

A Phase 2 clinical trial evaluating decitabine for Leukemia, Myeloid, Acute and Myelodysplastic Syndromes. Completed, enrolled 114 participants across 1 site.

Detailed Summary

This clinical trial studies potential genetic markers which might be used to predict which patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine. This study will contribute to the efforts to find effective and less toxic therapies to provide durable remissions in a significant proportion of elderly AML patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute, Myelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2012
Enrollment StartFeb 12, 2013
Primary CompletionJun 23, 2017
Study CompletionNov 13, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.8 years ago

Interventions

decitabinedrug